Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cidofovir · 3 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Cidofovir | DRUG | - |
| Probenecid | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral agents. * Oral trimethoprim/sulfamethoxazole. * Aerosolized pentamidine. * Dapsone. * Fluconazole. * Rifabutin. * Filgrastim (G-CSF). * p24 vaccine. Patients must have: * Diagnosis of AIDS by CDC criteria. * Diagnosis of periph...
Cidofovir is an investigational small molecule being studied for infectious diseases, specifically cytomegalovirus retinitis, HIV infections, and herpes simplex. It is being developed by Gilead Sciences, Inc. (NASDAQ: GILD). The drug is currently in Phase 2 clinical development for these indications.
Cidofovir is a small molecule antiviral agent. It works by inhibiting viral DNA polymerase, an enzyme essential for viral replication. This mechanism makes it potentially useful against DNA viruses such as cytomegalovirus and herpes simplex virus.
Cidofovir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol GILD. Gilead is conducting clinical trials to evaluate the safety and efficacy of Cidofovir for treating viral infections.
Cidofovir is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The most advanced completed trial was a Phase 2 study in patients with cytomegalovirus retinitis and HIV infections.
Cidofovir has been studied in three completed clinical trials. NCT00002437 was a Phase 2 study in cytomegalovirus retinitis and HIV infections with 48 participants. NCT00002116 and NCT00002327 were Phase 1 studies in herpes simplex and HIV, and in HIV with condyloma acuminata, respectively.
Yes, Cidofovir is also known as HPMPC, which stands for 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine dihydrate. This alternative name appears in clinical trial records, such as NCT00002116, which evaluated topical HPMPC for refractory mucocutaneous herpes simplex in AIDS patients.